2 results match your criteria: "Biomedical Research Institute of Salamanca and Spanish Network on Mastocytosis (REMA)[Affiliation]"
Unmet Clinical Needs and Management Recommendations for Blastic Plasmacytoid Dendritic Cell Neoplasm: A Consensus-based Position Paper From an Ad Hoc International Expert Panel.
Hemasphere
March 2023
Center for the Study of Myelofibrosis, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a hematological malignancy characterized by recurrent skin nodules, an aggressive clinical course with rapid involvement of hematological organs, and a poor prognosis with overall survival. The rarity of the disease results in a few large-scale studies, a lack of controlled clinical trials for its management, and a lack of evidence-based guidelines. Here, we present a review of unmet clinical needs on the management of BPDCN by a panel of eleven experts involved in the research and clinical practice of BPDCN.
View Article and Find Full Text PDFComprehensive Analysis of Acquired Genetic Variants and Their Prognostic Impact in Systemic Mastocytosis.
Cancers (Basel)
May 2022
Cancer Research Center (IBMCC, USAL/CSIC), Department of Medicine, Universidad de Salamanca, Biomedical Research Institute of Salamanca and Spanish Network on Mastocytosis (REMA), 37007 Salamanca, Spain.
Article Synopsis
- Systemic mastocytosis (SM) is a rare disease caused by mutations in the KIT gene (most commonly KIT D816V), which is found in over 90% of adult patients and drives the disease's progression.
- The presence of the KIT D816V mutation during blood cell development can lead to a higher tumor burden and other genetic mutations, increasing the risk of progression to advanced forms of SM.
- Identifying specific gene mutations (like ASXL1, CBL, DNMT3A, etc.) alongside KIT D816V can help predict patient outcomes and identify those who may need closer monitoring and early treatment.